Association of single nucleotide variants in VEGFA and KDR with the risk and angiogenic features of diffuse large B-cell lymphoma

References

• Alaggio R, Amador C, Anagnostopoulos I, et al. The 5th edition of the World Health Organization classification of haematolymphoid tumours: lymphoid neoplasms. Leukemia. 2022;36(7):1720–1748. doi:10.1038/s41375-022-01620-2
   PubMed Web of Science ®Google Scholar
• Skibola CF, Curry JD, Nieters A. Genetic susceptibility to lymphoma. Haematologica. 2007;92(7):960–969. doi:10.3324/haematol.11011
   PubMed Web of Science ®Google Scholar
• Hanahan D. Hallmarks of cancer: new dimensions. Cancer Discov. 2022;12(1):31–46. doi:10.1158/2159-8290.CD-21-1059
   PubMed Web of Science ®Google Scholar
• Schmidt T, Carmeliet P. Angiogenesis: a target in solid tumors, also in leukemia? Hematology Am Soc Hematol Educ Program. 2011;2011:1–8. doi:10.1182/asheducation-2011.1.1
   PubMedGoogle Scholar
• Zhao Y, Adjei AA. Targeting angiogenesis in cancer therapy: moving beyond vascular endothelial growth factor. Oncologist. 2015;20(6):660–673. doi:10.1634/theoncologist.2014-0465
   PubMed Web of Science ®Google Scholar
• Jiang L, Li N. B-cell non-Hodgkin lymphoma: importance of angiogenesis and antiangiogenic therapy. Angiogenesis. 2020;23(4):515–529. doi:10.1007/s10456-020-09729-7
   PubMed Web of Science ®Google Scholar
• Shahbazi M, Fryer AA, Pravica V, et al. Vascular endothelial growth factor gene polymorphisms are associated with acute renal allograft rejection. J Am Soc Nephrol. 2002;13(1):260–264. doi:10.1681/ASN.V131260
   PubMed Web of Science ®Google Scholar
• Kim YS, Park SW, Kim MH, et al. Novel single nucleotide polymorphism of the VEGF gene as a risk predictor for gastroduodenal ulcers. J Gastroenterol Hepatol. 2008;23(Suppl. 2):S131–S139. doi:10.1111/j.1440-1746.2008.05404.x
   PubMedGoogle Scholar
• Yoon KA, Kim MK, Eom HS, et al. Adverse prognostic impact of vascular endothelial growth factor gene polymorphisms in patients with diffuse large B-cell lymphoma. Leuk Lymphoma. 2017;58(11):2677–2682. doi:10.1080/10428194.2017.1300893
   PubMed Web of Science ®Google Scholar
• Qin C, Chen J, Li J, et al. Variants in angiogenesis-related genes and the risk of clear cell renal cell carcinoma. Mutagenesis. 2014;29(6):419–425. doi:10.1093/mutage/geu046
   PubMed Web of Science ®Google Scholar
• di Stefano AL, Labussiere M, Lombardi G, et al. VEGFA SNP rs2010963 is associated with vascular toxicity in recurrent glioblastomas and longer response to bevacizumab. J Neurooncol. 2015;121(3):499–504. doi:10.1007/s11060-014-1677-x
   PubMed Web of Science ®Google Scholar
• Steffensen KD, Waldstrøm M, Brandslund I, et al. The relationship of VEGF polymorphisms with serum VEGF levels and progression-free survival in patients with epithelial ovarian cancer. Gynecol Oncol. 2010;117(1):109–116. doi:10.1016/j.ygyno.2009.11.011
   PubMed Web of Science ®Google Scholar
• An S-J, Chen Z-H, Lin Q-X, et al. The –271 G > A polymorphism of kinase insert domain-containing receptor gene regulates its transcription level in patients with non-small cell lung cancer. BMC Cancer. 2009;9:144. doi:10.1186/1471-2407-9-144
   PubMed Web of Science ®Google Scholar
• Wang Y, Zheng Y, Zhang W, et al. Polymorphisms of KDR gene are associated with coronary heart disease. J Am Coll Cardiol. 2007;50(8):760–767. doi:10.1016/j.jacc.2007.04.074
   PubMed Web of Science ®Google Scholar
• Brito ABC, Delamain MT, Fanelli MF, et al. Angiogenesis’ related genetic variants alter clinical features and prognosis of diffuse large B-cell lymphoma patients. Tumour Biol. 2021;43(1):129–140. doi:10.3233/TUB-211510
   PubMedGoogle Scholar
• Vasconcelos VCA, Lourenço GJ, Brito ABC, et al. Associations of VEGFA and KDR single-nucleotide polymorphisms and increased risk and aggressiveness of high-grade gliomas. Tumour Biol. 2019;41(9):1010428319872092. doi:10.1177/1010428319872092
   Google Scholar
• Song Y, Hu J, Chen Q, et al. Association between vascular endothelial growth factor rs699947 polymorphism and the risk of three major urologic neoplasms (bladder cancer, prostate cancer, and renal cell carcinoma): a meta-analysis involving 11,204 subjects. Gene. 2018;679:241–252. doi:10.1016/j.gene.2018.09.005
   PubMed Web of Science ®Google Scholar
• Pădureanu V, Boldeanu MV, Streaţă I, et al. Determination of VEGFR-2 (KDR) 604A > G polymorphism in pancreatic disorders. Int J Mol Sci. 2017;18:439. doi:10.3390/ijms18020439
   PubMed Web of Science ®Google Scholar
• Hong TT, Zhang RX, Wu XH, et al. Polymorphism of vascular endothelial growth factor 21154G > A (rs1570360) with cancer risk: a meta-analysis of 16 case-control studies. Mol Biol Rep. 2012;39(5):5283–5289. doi:10.1007/s11033-011-1326-9
   PubMed Web of Science ®Google Scholar
• Faber EW, Lourenço GJ, Ortega MM, et al. Polymorphisms of VEGF, GSTM1 and GSTT1 genes in multiple myeloma risk. Hematol Oncol. 2012;30(2):105–107. doi:10.1002/hon.1009
   PubMed Web of Science ®Google Scholar
• Brito ABC, Lourenço GJ, Oliveira GB, et al. Associations of VEGF and VEGFR2 polymorphisms with increased risk and aggressiveness of multiple myeloma. Ann Hematol. 2014;93(8):1363–1369. doi:10.1007/s00277-014-2062-8
   PubMed Web of Science ®Google Scholar
• Lopes-Aguiar L, Delamain MT, Brito ABC, et al. VEGF, VEGFR2 and GSTM1 polymorphisms in outcome of multiple myeloma patients treated with thalidomide-based regimens. Blood Cancer J. 2017;7(6):e580. doi:10.1038/bcj.2017.58
   PubMedGoogle Scholar
• de Mendonça GRA, Brito ABC, Rocha RM, et al. Association of VEGFA-2578 C > A polymorphism with clinicopathological aspects and outcome in follicular lymphoma patients. Blood Cancer J. 2016;6(8):e464. doi:10.1038/bcj.2016.76
   PubMedGoogle Scholar
• WHO Classification of Tumors Editorial Board. Haematolymphoid tumors [Internet; beta version ahead of print]. Lyon (France): International Agency for Research on Cancer; 2022 [cited 2023 August 22]. (WHO classification of tumors series, 5th ed.; vol. 11). Available from: https://tumourclassification.iarc.who.int/chapters/63.
   Google Scholar
• Hans CP, Weisenburger DD, Greiner TC, et al. Confirmation of the molecular classification of diffuse large B-cell lymphoma by immunohistochemistry using a tissue microarray. Blood. 2004;103(1):275–282. doi:10.1182/blood-2003-05-1545
   PubMed Web of Science ®Google Scholar
• Cheson BD, Fisher RI, Barrington SF, et al. Recommendations for initial evaluation, staging, and response assessment of Hodgkin and non-Hodgkin lymphoma: the Lugano classification. J Clin Oncol. 2014;32(27):3059–3068. doi:10.1200/JCO.2013.54.8800
   PubMed Web of Science ®Google Scholar
• Sehn LH, Berry B, Chhanabhai M, et al. The Revised International Prognostic Index (R-IPI) is a better predictor of outcome than the standard IPI for patients with diffuse large B-cell lymphoma treated with R-CHOP. Blood. 2007;109(5):1857–1861. doi:10.1182/blood-2006-08-038257
   PubMed Web of Science ®Google Scholar
• Varghese F, Bukhari AB, Malhotra R, et al. IHC profiler: an open source plugin for the quantitative evaluation and automated scoring of immunohistochemistry images of human tissue samples. PLOS One. 2014;9(5):e96801. doi:10.1371/journal.pone.0096801
   PubMed Web of Science ®Google Scholar
• Menzel L, Höpken UE, Rehm A. Angiogenesis in lymph nodes is a critical regulator of immune response and lymphoma growth. Front Immunol. 2020;11:591741. doi:10.3389/fimmu.2020.591741
   PubMed Web of Science ®Google Scholar
• Solimando AG, Annese T, Tamma R, et al. New insights into diffuse large B-cell lymphoma pathobiology. Cancers. 2020;12:1–22. doi:10.3390/cancers12071869
   Web of Science ®Google Scholar
• Tzankov A, Heiss S, Ebner S, et al. Angiogenesis in nodal B cell lymphomas: a high throughput study. J Clin Pathol. 2007;60(5):476–482. doi:10.1136/jcp.2006.038661
   PubMed Web of Science ®Google Scholar
• Gratzinger D, Zhao S, Tibshirani RJ, et al. Prognostic significance of VEGF, VEGF receptors, and microvessel density in diffuse large B cell lymphoma treated with anthracycline-based chemotherapy. Lab Invest. 2008;88(1):38–47. doi:10.1038/labinvest.3700697
   PubMed Web of Science ®Google Scholar
• Yang Y, Li SS, Chien JW, et al. A systematic search for SNPs/haplotypes associated with disease phenotypes using a haplotype-based stepwise procedure. BMC Genet. 2008;9:90. doi:10.1186/1471-2156-9-90
   PubMed Web of Science ®Google Scholar
• Purdum A, Tieu R, Reddy SR, et al. Direct costs associated with relapsed diffuse large B-cell lymphoma therapies. Oncologist. 2019;24(9):1229–1236. doi:10.1634/theoncologist.2018-0490
   PubMed Web of Science ®Google Scholar
• Kanas G, Ge W, Quek RGW, et al. Epidemiology of diffuse large B-cell lymphoma (DLBCL) and follicular lymphoma (FL) in the United States and Western Europe: population-level projections for 2020–2025. Leuk Lymphoma, 2022;63(1):54–63. doi:10.1080/10428194.2021.1975188
   PubMed Web of Science ®Google Scholar
• Giatromanolaki A, Koukourakis MI, Pezzella F, et al. Phosphorylated VEGFR2/KDR receptors are widely expressed in B-cell non-Hodgkin’s lymphomas and correlate with hypoxia inducible factor activation. Hematol Oncol. 2008;26(4):219–224. doi:10.1002/hon.861
   PubMed Web of Science ®Google Scholar
• Xavier FD, Levy D, Pereira J. Time-to-treatment of diffuse large B-cell lymphoma in São Paulo. Clinics. 2014;69(5):367–371. doi:10.6061/clinics/2014(05)12
   PubMed Web of Science ®Google Scholar
• Bernardo PS, Hancio T, Vasconcelos FDC, et al. Primary diffuse large B-cell lymphoma of the head and neck in a Brazilian Single-Center Study. Oral Dis. 2023;29(3):968–977. doi:10.1111/odi.14104
   PubMed Web of Science ®Google Scholar
• Cardozo DM, Marangon AV, Guimarães F, et al. Association of KIR genes polymorphism and its HLA ligands in diffuse large B-cell lymphoma. Clin Lymphoma Myeloma Leuk. 2023;23(6):438–445.
   PubMed Web of Science ®Google Scholar
• Laurini JA, Perry AM, Boilesen E, et al. Classification of non-Hodgkin lymphoma in Central and South America: a review of 1028 cases. Blood. 2012;120(24):4795–4801. doi:10.1182/blood-2012-07-440073
   PubMed Web of Science ®Google Scholar
• Cabrera ME, Peña C, Leon P, et al. Diffuse large B-cell lymphoma in Chile: the impact of combined CHOP plus rituximab in the public health system. J Clin Oncol Glob Oncol. 2022;8:e2200165.
   PubMedGoogle Scholar
• Galimberti S, Nagy B, Palumbo GA, et al. Vascular endothelial growth factor polymorphisms in mantle cell lymphoma. Acta Haematol. 2010;123(2):91–95. doi:10.1159/000267826
   PubMed Web of Science ®Google Scholar
• Kim MK, Suh C, Chi HS, et al. VEGFA and VEGFR2 genetic polymorphisms and survival in patients with diffuse large B cell lymphoma. Cancer Sci. 2012;103(3):497–503. doi:10.1111/j.1349-7006.2011.02168.x
   PubMed Web of Science ®Google Scholar
• Sun S, Li X, Qu B, et al. Association of the VEGFR2 single nucleotide polymorphism rs2305948 with glioma risk. Medicine. 2022;101(1):e28454. doi:10.1097/MD.0000000000028454
   PubMed Web of Science ®Google Scholar
• Sudhesan A, Rajappa M, Chandrashekar L, et al. Vascular endothelial growth factor (VEGF) gene polymorphisms (rs699947, rs833061, and rs2010963) and psoriatic risk in South Indian Tamils. Hum Immunol. 2017;78(10):657–663. doi:10.1016/j.humimm.2017.08.004
   PubMed Web of Science ®Google Scholar
• Al-Habboubi HH, Sater MS, Almawi AW, et al. Contribution of VEGF polymorphisms to variation in VEGF serum levels in a healthy population. Eur Cytokine Netw. 2011;22(3):154–158. doi:10.1684/ecn.2011.0289
   PubMed Web of Science ®Google Scholar
• Davis RE, Brown KD, Siebenlist U, et al. Constitutive nuclear factor κB activity is required for survival of activated B cell-like diffuse large B cell lymphoma cells. J Exp Med. 2001;194(12):1861–1874. doi:10.1084/jem.194.12.1861
   PubMed Web of Science ®Google Scholar
• Lenz G, Wright G, Dave SS, et al. Stromal gene signatures in large-B-cell lymphomas. N Engl J Med. 2008;359(22):2313–2323. doi:10.1056/NEJMoa0802885
   PubMed Web of Science ®Google Scholar
• Karin M. Nuclear factor-κB in cancer development and progression. Nature. 2006;441(7092):431–436. doi:10.1038/nature04870
   PubMed Web of Science ®Google Scholar
• Jørgensen JM, Sørensen FB, Bendix K, et al. Angiogenesis in non-Hodgkin’s lymphoma: clinico-pathological correlations and prognostic significance in specific subtypes. Leuk Lymphoma. 2007;48(3):584–595. doi:10.1080/10428190601083241
   PubMed Web of Science ®Google Scholar